Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
69 hedge funds and large institutions have $334M invested in Revance Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 14 reducing their positions, and 23 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 14
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
11% more capital invested
Capital invested by funds: $301M → $334M (+$32.8M)
14% less funds holding
Funds holding: 80 → 69 (-11)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $46K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$23.9M |
| 2 |
VAM
Visium Asset Management
New York
|
+$17.5M |
| 3 |
Bank of New York Mellon
New York
|
+$16.4M |
| 4 |
PC
Polar Capital
London,
United Kingdom
|
+$7.29M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$19.9M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$10.9M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
-$8.15M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$7.51M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$5.38M |
RVNC Hedge Fund Activity: Q4 2014 in Review
69 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q4 2014, worth a combined $334M — up 11% from $301M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of RVNC and 12 opened new positions — a net loss of 11 holders — while 14 trimmed existing stakes and 32 added.
The largest buyer was Franklin Resources, adding an estimated $23.9M. The largest seller was Fidelity Investments, exiting entirely with an estimated $19.9M sold.
- 69 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q4 2014, down from 80 in Q3 2014.
- Funds reported $334M of Revance Therapeutics, Inc. stock for Q4 2014, up 11% quarter-over-quarter.
- 12 funds opened new Revance Therapeutics, Inc. positions in Q4 2014 and 23 closed out, a net change of -11 holders.
- The largest Revance Therapeutics, Inc. buyer in Q4 2014 was Franklin Resources, an estimated $23.9M added.
- The largest Revance Therapeutics, Inc. seller in Q4 2014 was Fidelity Investments, an estimated $19.9M sold.
Based on aggregated 13F filings for Q4 2014.